$46.19 -$0.62 (-1.3%)

04:00 PM EST on 11/20/19

ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)

CAPS Rating: 2 out of 5

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Current Price $46.19 Mkt Cap $7.2B
Open $46.41 P/E Ratio 0.00
Prev. Close $46.81 Div. (Yield) $0.00 (0.0%)
Daily Range $45.50 - $47.14 Volume 1,760,898
52-Wk Range $15.73 - $47.79 Avg. Daily Vol. 1,526,689

Caps

How do you think NASDAQ:ACAD will perform against the market?

Add Stock to CAPS Watchlist

All Players

282 Outperform
76 Underperform
 

All-Star Players

39 Outperform
16 Underperform
 

Wall Street

7 Outperform
2 Underperform
 

Top NASDAQ:ACAD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

MarkBiotech (< 20)
Submitted April 05, 2017

Nuplazid is the first drug approved for the treatment of PD psychosis. This market represents a 2-3B peak in sales. If Pimavanserin successfully expands its label to Alzheimer psychosis, Alzheimer agitation, schizo IRAT, then you have a company with… More

constructive (99.97)
Submitted March 03, 2017

This article does a good job of laying out the bear case: http://seekingalpha.com/article/4015176-acadias-nuplazid-blockbuster-drug-imaginedThe market may turn out to be smaller than expected, especially with the black box warning ("Side effects… More

Recent Community Commentary

Read the most recent pitches from players about ACAD.

Recs

0
Member Avatar jahnjf (46.31) Submitted: 4/30/2018 4:19:11 PM : Outperform Start Price: $15.84 NASDAQ:ACAD Score: +173.86

Currently slightly overvalued but if willing to risk that it gets approval for treatment of dementia and Alzheimer's, it will be an outperformer.

Recs

1
Member Avatar MarkBiotech (< 20) Submitted: 4/5/2017 3:48:38 AM : Outperform Start Price: $29.43 NASDAQ:ACAD Score: +27.17

Nuplazid is the first drug approved for the treatment of PD psychosis. This market represents a 2-3B peak in sales. If Pimavanserin successfully expands its label to Alzheimer psychosis, Alzheimer agitation, schizo IRAT, then you have a company with unlimited potential.

2nd half of 2016 sales on Nuplazid were encouraging and prompted more confidence in my long position in Acadia. Nuplazid consensus of 90m sales in 2017 seems very conservative. All said and done, Acadia seems to be on the right track to becoming a pharmaceutical powerhouse.

LT Closing limit PT- 100

Recs

2
Member Avatar constructive (99.97) Submitted: 3/3/2017 4:05:27 PM : Underperform Start Price: $4.83 NASDAQ:ACAD Score: -741.12

This article does a good job of laying out the bear case: http://seekingalpha.com/article/4015176-acadias-nuplazid-blockbuster-drug-imagined

The market may turn out to be smaller than expected, especially with the black box warning ("Side effects include death"). Most of the market is covered by Medicare, and pricing could be under pressure. Cash burn is also very high.

Leaderboard

Find the members with the highest scoring picks in ACAD.

Score Leader

jamrod02

jamrod02 (64.28) Score: +5,750.20

The Score Leader is the player with the highest score across all their picks in ACAD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
jamrod02 64.28 12/20/2010 Outperform 5Y $0.77 +5,899.48% +149.28% +5,750.20 0 Comment
noobtery < 20 10/28/2010 Outperform 5Y $0.83 +5,465.06% +161.40% +5,303.66 0 Comment
Hornet41 61.35 12/22/2010 Outperform 5Y $0.90 +5,031.65% +147.61% +4,884.04 0 Comment
Ruckwerts 60.49 12/1/2011 Outperform 3Y $0.93 +4,866.67% +149.02% +4,717.65 0 Comment
dsherid2 59.41 11/30/2011 Outperform 1Y $1.03 +4,384.90% +150.08% +4,234.82 0 Comment
Smog79 < 20 8/12/2010 Outperform 3W $1.04 +4,341.35% +186.07% +4,155.28 0 Comment
drmanand 64.52 7/14/2010 Outperform 1Y $1.11 +4,062.01% +184.24% +3,877.77 1 Comment
smallandmidcap 95.37 8/10/2010 Outperform 5Y $1.13 +3,987.61% +177.34% +3,810.27 0 Comment
dmkj50 41.15 10/27/2011 Outperform 5Y $1.17 +3,847.53% +142.87% +3,704.66 0 Comment
tappo3833 88.89 1/3/2011 Outperform 1Y $1.19 +3,781.51% +145.21% +3,636.31 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ACAD.